quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·178d
PRRelease
Bicara Therapeutics Inc. logo
IO Biotech Inc. logo
Novartis AG logo
+1

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

BCAX· Bicara Therapeutics Inc.IOBT· IO Biotech Inc.NVS· Novartis AGPFE· Pfizer Inc.
Health Care
Original source

Companies

  • BCAX
    Bicara Therapeutics Inc.
    Health Care
  • IOBT
    IO Biotech Inc.
    Health Care
  • NVS
    Novartis AG
    Health Care
  • PFE
    Pfizer Inc.
    Health Care

Recent analyst ratings

  • Mar 25BCAXUpdateBofA Securities$35.00
  • Mar 11NVSUpdateArgus$180.00
  • Mar 2PFEUpdateArgus$35.00
  • Feb 25PFEUpdateRBC Capital Mkts$25.00
  • Feb 20PFEUpdateBarclays$25.00
  • Feb 12PFEUpdateDaiwa Securities$27.00

Related

  • INSIDER1d
    SEC Form 4 filed by Hyep Ivan
  • PR1d
    Pfizer Declares Second-Quarter 2026 Dividend
  • PR2d
    Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
  • INSIDER3d
    SEC Form 4 filed by Mazumdar Claire
  • SEC3d
    SEC Form 144 filed by Bicara Therapeutics Inc.
  • PR3d
    U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
  • INSIDER6d
    SEC Form 4 filed by Cohlhepp Ryan
  • INSIDER6d
    SEC Form 4 filed by Bourla Albert
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022